Ticker League

Regeneron Pharmaceuticals (REGN) Free Cash Flow Bridge

Pinpoint what moved Regeneron Pharmaceuticals's free cash flow from TTM through Q1 2025 to TTM through Q1 2026 — operating cash flow shifts and capex changes, each driver sized in dollars.

FCF YoY

+37.58%

OCF YoY

+26.80%

Capex YoY

-8.09%

FCF Conversion Δ

+6.5 pp

Free cash flow bridge for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Free cash flow: $1.14B

FCF bridge breakdown for Regeneron Pharmaceuticals (REGN) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Free Cash Flow$3.02B
  • Operating Cash Flow$1.06B
  • Capital Expenditure$75.50M
  • Free Cash Flow$4.16B
Identity check: drivers reconcile to ΔNI within $0.00
Want to see how cash flow is built up?Cash Flow Waterfall

Frequently asked questions

Data & methodology